Altimmune, Inc.
$3.56
▲
7.05%
2026-04-21 05:15:00
altimmune.com
NGM: ALT
Explore Altimmune, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$463.05 M
Current Price
$3.56
52W High / Low
$7.73 / $2.87
Stock P/E
—
Book Value
$2.03
Dividend Yield
—
ROCE
-35.67%
ROE
-50.57%
Face Value
—
EPS
$-1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
57
Beta
0.34
Debt / Equity
15.87
Current Ratio
18.55
Quick Ratio
18.55
Forward P/E
-2.37
Price / Sales
10,281.48
Enterprise Value
$183.66 M
EV / EBITDA
-1.95
EV / Revenue
4,479.48
Rating
Buy
Target Price
$18
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
| 2. | Tonix Pharmaceuticals Holding Corp. | $14.34 | — | $184.59 M | — | -49.81% | -64.48% | $69.97 / $11.6 | $19.17 |
| 3. | CG Oncology, Inc. | $70.4 | — | $6.2 B | — | -25.08% | -21.67% | $73.56 / $19.47 | $9.33 |
| 4. | Arvinas, Inc. | $10.81 | — | $703.57 M | — | -20.59% | -16.23% | $14.51 / $5.9 | $6.83 |
| 5. | Alto Neuroscience, Inc. | $27.33 | — | $885.53 M | — | -38.28% | -41.8% | $28.11 / $2.09 | $4.74 |
| 6. | Arcus Biosciences, Inc. | $22.74 | — | $2.85 B | — | -42.51% | -63.26% | $26.4 / $7.06 | $5.04 |
| 7. | Kezar Life Sciences, Inc. | $7.29 | — | $53.74 M | — | -74.59% | -59.93% | $7.55 / $3.53 | $9.56 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.03 M | 0.01 M | 0.01 M | 0.01 M | 0.01 M | — |
| Operating Profit | -28.89 M | -20.86 M | -22.92 M | -21.82 M | -24.87 M | — |
| Net Profit | -27.36 M | -19.01 M | -22.15 M | -19.57 M | -23.18 M | — |
| EPS in Rs | -0.21 | -0.15 | -0.17 | -0.15 | -0.18 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.04 M | 0.02 M | 0.43 M | -0.07 M |
| Operating Profit | -94.49 M | -103.17 M | -83.51 M | -87.74 M |
| Net Profit | -88.09 M | -95.06 M | -88.45 M | -84.71 M |
| EPS in Rs | -0.68 | -0.73 | -0.68 | -0.65 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 279.93 M | 139.31 M | 210.64 M | 206.93 M |
| Total Liabilities | 55.04 M | 15.8 M | 16.54 M | 21.64 M |
| Equity | 224.89 M | 123.51 M | 194.1 M | 185.29 M |
| Current Assets | 278.19 M | 137.25 M | 209.63 M | 192.81 M |
| Current Liabilities | 15 M | 10.47 M | 12.14 M | 17.05 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -67.53 M | -79.85 M | -75.81 M | -62.59 M |
| Investing CF | -132.47 M | -28.39 M | 13.73 M | -73.4 M |
| Financing CF | 206.84 M | 10.04 M | 86.11 M | 56.78 M |
| Free CF | -67.55 M | -79.85 M | -75.86 M | -62.71 M |
| Capex | -0.01 M | — | -0.05 M | -0.13 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -95.31% | 726.47% | — | — |
| Earnings Growth % | -7.48% | -4.41% | — | — |
| Profit Margin % | -475295% | -20762.21% | 124577.94% | — |
| Operating Margin % | -515860% | -19603.29% | 129029.41% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -474060% | -20642.02% | 124130.88% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.